Compounds > tazifylline
Page last updated: 2024-12-06

tazifylline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID54424
CHEMBL ID155962
SCHEMBL ID141489
MeSH IDM0139258

Synonyms (43)

Synonym
tazifylline
taziphylline
CHEMBL155962
7-[2-hydroxy-3-[4-(3-phenylsulfanylpropyl)piperazin-1-yl]propyl]-1,3-dimethylpurine-2,6-dione
tazifyllinum [latin]
tazifyllinum
tazifilina [spanish]
tazifylline [inn]
unii-f45ox6fzwp
1h-purine-2,6-dione, 3,7-dihydro-7-(2-hydroxy-3-(4-(3-(phenylthio)propyl)-1-piperazinyl)propyl)-1,3-dimethyl-
f45ox6fzwp ,
79712-55-3
tazifilina
SCHEMBL141489
3,7-dihydro-7-(2-hydroxy-3-(4-(3-(phenylthio)propyl)-1-piperazinyl)propyl)-1,3-dimethyl-1h-purine-2,6-dione
7-[3-[4-(3-phenylthiopropyl)-1-piperazinyl]-2-hydroxypropyl]-theophylline
JTOUASWUIMAMAD-UHFFFAOYSA-N
7-[3-[4-(3-phenylthiopropyl)-1-piperazinyl]-2-hydroxypropyl]theophylline
sr-01000883697
SR-01000883697-1
CS-6582
HY-U00018
( inverted exclamation marka)-tazifylline
((plusmn))-tazifylline
(+)-tazifylline
113932-16-4
113932-15-3
1h-purine-2,6-dione, 3,7-dihydro-7-(2-hydroxy-3-(4-(3-(phenylthio)propyl)-1-piperazinyl)propyl)-1,3-dimethyl-, (+)-
tazifylline, (-)-
tazifylline, (+)-
1h-purine-2,6-dione, 3,7-dihydro-7-(2-hydroxy-3-(4-(3-(phenylthio)propyl)-1-piperazinyl)propyl)-1,3-dimethyl-, (-)-
(-)-tazifylline
CT45R338RA ,
(+)-3,7-dihydro-7-(2-hydroxy-3-(4-(3-(phenylthio)propyl)-1-piperazinyl)propyl)-1,3-dimethyl-1h-purine-2,6-dione
QM9XEZ4469 ,
(-)-3,7-dihydro-7-(2-hydroxy-3-(4-(3-(phenylthio)propyl)-1-piperazinyl)propyl)-1,3-dimethyl-1h-purine-2,6-dione
Q27277613
unii-qm9xez4469
unii-ct45r338ra
DTXSID00868541
7-(2-hydroxy-3-{4-[3-(phenylsulfanyl)propyl]piperazin-1-yl}propyl)-1,3-dimethyl-3,7-dihydro-1h-purine-2,6-dione
AKOS040732213
(??)-tazifylline

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"6 h consistent with twice-daily dosing of tazifylline."( Multiple-dose pharmacokinetics of the new H1-receptor antagonist tazifylline in healthy volunteers.
Auger, J; Bruno, R; Cano, JP; Dow, R; Iliadis, A; Jullien, I; McEwen, J; Pinhas, H, )		0.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID188845Percent protection against Passive Cutaneous Anaphylaxis in rat after 4.0h at dose 100 mg/kg by peroral administration through antigen or antibody reaction1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
New antihistaminic theophylline or theobromine derivatives.
AID188838Percent protection against Passive Cutaneous Anaphylaxis in rat after 0.25 hr at dose 100 mg/kg by peroral administration through exogenous histamine reaction1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
New antihistaminic theophylline or theobromine derivatives.
AID188840Percent protection against Passive Cutaneous Anaphylaxis in rat after 1.0 hr at dose 100 mg/kg by peroral administration through exogenous histamine reaction1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
New antihistaminic theophylline or theobromine derivatives.
AID173539Percent decrease in antiallergic activity by antigen/antibody reaction assay in rat by oral administration at a dose of 10 mg/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
New antihistaminic theophylline or theobromine derivatives.
AID188843Percent protection against Passive Cutaneous Anaphylaxis in rat after 3.0 hh at dose 100 mg/kg by peroral administration through antigen or antibody reaction1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
New antihistaminic theophylline or theobromine derivatives.
AID188841Percent protection against Passive Cutaneous Anaphylaxis in rat after 2.0 hr at dose 100 mg/kg by peroral administration through antigen or antibody reaction1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
New antihistaminic theophylline or theobromine derivatives.
AID173540Percentage decrease in antiallergic activity against cutaneous reaction to histamine in rat, by oral administration at a dose of 10 mg/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
New antihistaminic theophylline or theobromine derivatives.
AID188839Percent protection against Passive Cutaneous Anaphylaxis in rat after 1.0 hr at dose 100 mg/kg by peroral administration through antigen or antibody reaction1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
New antihistaminic theophylline or theobromine derivatives.
AID188846Percent protection against Passive Cutaneous Anaphylaxis in rat after 4.0h at dose 100 mg/kg by peroral administration through exogenous histamine reaction1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
New antihistaminic theophylline or theobromine derivatives.
AID75528Percent decrease in bronchodilator activity against histamine-induced bronchospasm reaction in guinea pig by intraveneous administration at dose 250 ug/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
New antihistaminic theophylline or theobromine derivatives.
AID188842Percent protection against Passive Cutaneous Anaphylaxis in rat after 2.0 hr at dose 100 mg/kg by peroral administration through exogenous histamine reaction1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
New antihistaminic theophylline or theobromine derivatives.
AID75527Percent decrease in bronchodilator activity against acetylcholine-induced bronchospasm reaction in guinea pig by intraveneous administration at dose 250 ug/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
New antihistaminic theophylline or theobromine derivatives.
AID75529Percentage decrease in bronchodilator activity against serotonin-induced bronchospasm reaction in guinea pig by intraveneous administration at dose 250 ug/kg1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
New antihistaminic theophylline or theobromine derivatives.
AID188837Percent protection against Passive Cutaneous Anaphylaxis in rat after 0.25 hr at dose 100 mg/kg by peroral administration through antigen or antibody reaction1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
New antihistaminic theophylline or theobromine derivatives.
AID188844Percent protection against Passive Cutaneous Anaphylaxis in rat after 3.0 hh at dose 100 mg/kg by peroral administration through exogenous histamine reaction1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
New antihistaminic theophylline or theobromine derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.05 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (42.86%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (57.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
histamine
[no description available]		8.3611aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
theophylline
[no description available]		5.5263dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
chlorpheniramine
Chlorpheniramine: A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.. chlorphenamine : A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma.		1.9610monochlorobenzenes;
pyridines;
tertiary amino compound		anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		1.96101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
ketotifen
Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.. ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.		1.9610cyclic ketone;
olefinic compound;
organic heterotricyclic compound;
organosulfur heterocyclic compound;
piperidines;
tertiary amino compound		anti-asthmatic drug;
H1-receptor antagonist
promethazine
Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.		1.9610phenothiazines;
tertiary amine		anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative
terfenadine
Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.		1.9610diarylmethane
triprolidine
Triprolidine: Histamine H1 antagonist used in allergic rhinitis; ASTHMA; and URTICARIA. It is a component of COUGH and COLD medicines. It may cause drowsiness.. triprolidine : An N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms of uticaria, rhinitis, and various pruritic skin disorders.		1.9610N-alkylpyrrolidine;
olefinic compound;
pyridines		H1-receptor antagonist
ConditionIndicatedRelationship StrengthStudiesTrials
Bronchospasm
[description not available]		01.9610
Bronchial Spasm
Spasmodic contraction of the smooth muscle of the bronchi.		01.9610
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		01.9610
Asthma, Bronchial
[description not available]		03.3611
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		08.3611
Eczema, Atopic
[description not available]		03.3511
Itching
[description not available]		03.3511
Dermatitis, Atopic
A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.		03.3511
Pruritus
An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.		03.3511
Atopic Hypersensitivity
[description not available]		03.3511